MM-093 ( DrugBank: MM-093 )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	2

46. 悪性関節リウマチ

---

臨床試験数 : 4,356 /  薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00458146 (ClinicalTrials.gov)	February 2007	5/4/2007	A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis	A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 60mg of MM-093 Versus Placebo in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate	Rheumatoid Arthritis	Drug: MM-093	Merrimack Pharmaceuticals	NULL	Completed	18 Years	80 Years	Both	100	Phase 2	United States
2	NCT00105976 (ClinicalTrials.gov)	February 2005	18/3/2005	Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)	A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Efficacy and Safety of 3 Different Dose Levels (2.5, 7.5 and 20 mg) of MM-093 in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate	Rheumatoid Arthritis	Drug: MM-093	Merrimack Pharmaceuticals	NULL	Completed	18 Years	80 Years	Both	260	Phase 2	United States